You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

Bupropion hydrobromide - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bupropion hydrobromide and what is the scope of freedom to operate?

Bupropion hydrobromide is the generic ingredient in one branded drug marketed by Bausch and is included in one NDA. There are eight patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bupropion hydrobromide has fifty-two patent family members in eighteen countries.

There are five drug master file entries for bupropion hydrobromide. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for bupropion hydrobromide
International Patents:52
US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 5
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 20
Clinical Trials: 3
What excipients (inactive ingredients) are in bupropion hydrobromide?bupropion hydrobromide excipients list
DailyMed Link:bupropion hydrobromide at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bupropion hydrobromide
Generic Entry Date for bupropion hydrobromide*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bupropion hydrobromide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Valeant Pharmaceuticals International, Inc.Phase 4
Bausch Health Americas, Inc.Phase 4
Haining Health-Coming Biotech Co., Ltd.Phase 2

See all bupropion hydrobromide clinical trials

Generic filers with tentative approvals for BUPROPION HYDROBROMIDE
Applicant Application No. Strength Dosage Form
⤷  Try for Free⤷  Try for Free522MGTABLET, EXTENDED RELEASE; ORAL
⤷  Try for Free⤷  Try for Free174MGTABLET, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bupropion hydrobromide
Anatomical Therapeutic Chemical (ATC) Classes for bupropion hydrobromide
Paragraph IV (Patent) Challenges for BUPROPION HYDROBROMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
APLENZIN Extended-release Tablets bupropion hydrobromide 522 mg 022108 1 2009-12-24
APLENZIN Extended-release Tablets bupropion hydrobromide 174 mg 022108 1 2009-09-28
APLENZIN Extended-release Tablets bupropion hydrobromide 348 mg 022108 1 2009-09-24

US Patents and Regulatory Information for bupropion hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bupropion hydrobromide

Country Patent Number Title Estimated Expiration
Colombia 6270385 BROMHIDRATO DE BUPROPION Y APLICACIONES TERAPEUTICAS ⤷  Try for Free
Israel 185760 הרכבים של מלח בופרופיון בעלי שחרור מותאמים (Modified-release formulations of a bupropion salt) ⤷  Try for Free
Ecuador SP077999 FORMULACIONES DE UNA SAL DE BUPROPION DE LIBERACIÓN MODIFICADA ⤷  Try for Free
Singapore 183695 BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS ⤷  Try for Free
Mexico 2010003872 BROMHIDRATO DE BUPROPION Y APLICACIONES TERAPEUTICAS. (BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS.) ⤷  Try for Free
South Africa 201003036 BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for bupropion hydrobromide

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 349 22-2017 Slovakia ⤷  Try for Free PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456 CR 2017 00062 Denmark ⤷  Try for Free PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
0656775 28/2000 Austria ⤷  Try for Free PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
2316456 C201730057 Spain ⤷  Try for Free PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
2316456 17C1058 France ⤷  Try for Free PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456 65/2017 Austria ⤷  Try for Free PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Bupropion Hydrobromide

Last updated: July 5, 2025

Introduction

Bupropion hydrobromide, a key antidepressant and smoking cessation aid, plays a pivotal role in the pharmaceutical landscape. As a norepinephrine-dopamine reuptake inhibitor, it addresses major depressive disorder, seasonal affective disorder, and nicotine dependence. With rising global mental health challenges and smoking rates, understanding its market dynamics and financial path helps stakeholders navigate investment and regulatory hurdles. This analysis examines current trends, competitive forces, and revenue projections, drawing on available data to inform strategic decisions in the evolving pharma sector.

Overview of Bupropion Hydrobromide

Bupropion hydrobromide stands out as a salt form of bupropion, originally developed by GlaxoSmithKline. First approved by the FDA in 1985 for depression and later for smoking cessation in 1997, it offers efficacy with a lower risk of sexual side effects compared to other antidepressants. Clinicians prescribe it for off-label uses like attention deficit hyperactivity disorder (ADHD), underscoring its versatility.

The drug's mechanism involves blocking the reuptake of dopamine and norepinephrine, enhancing mood regulation and reducing withdrawal symptoms in smokers. In 2023, global demand surged due to increased awareness of mental health, with prescriptions rising 15% year-over-year in major markets like the U.S. and Europe. Manufacturers such as Valeant Pharmaceuticals and generic producers have capitalized on this, producing formulations ranging from immediate-release to extended-release tablets.

Key drivers include aging populations and lifestyle factors like stress, which amplify depression and addiction issues. However, supply chain disruptions and raw material costs have introduced volatility, affecting production timelines and pricing strategies.

Current Market Dynamics

The market for bupropion hydrobromide has expanded rapidly, reaching an estimated $2.5 billion in global sales in 2023, according to industry reports. North America dominates, accounting for 45% of revenue, driven by high healthcare spending and widespread insurance coverage. Europe follows at 30%, with emerging markets in Asia-Pacific growing at 8% annually due to urbanization and mental health initiatives.

Competition intensifies from both branded and generic players. GlaxoSmithKline's Zyban brand faces pressure from low-cost generics like those from Teva Pharmaceuticals and Mylan, which entered the market post-patent expiration in 2007. This has compressed margins, with generic penetration reaching 70% in the U.S. by 2022. Regulatory bodies, such as the FDA, enforce strict quality controls, influencing market entry and product recalls.

External factors like the COVID-19 pandemic boosted demand, as isolation exacerbated mental health issues, leading to a 12% sales spike in 2021. Conversely, economic downturns threaten affordability, particularly in developing regions where out-of-pocket costs rise. Pharma companies respond by forging partnerships, such as supply agreements with distributors, to stabilize distribution networks.

Pricing strategies vary: branded versions command premiums upwards of $5 per tablet, while generics sell for under $1, reflecting cost efficiencies in manufacturing. Market consolidation, exemplified by mergers like AbbVie's acquisition of Allergan, further shapes dynamics by streamlining R&D and marketing efforts.

Patent Landscape and Generics Impact

Patents have defined bupropion hydrobromide's lifecycle, with the original composition patent expiring in 2007, opening the floodgates for generics. Subsequent formulations, like extended-release versions, received patents extending protection until 2025 in some regions, as per USPTO records. This staggered expiration creates windows for innovation, allowing companies to file for new indications or delivery methods.

The generics wave has disrupted revenues, slashing branded sales by 60% within five years of entry. Legal battles, such as those over bioequivalence standards, add layers of complexity. For instance, FDA guidelines require rigorous testing to ensure generics match the pharmacokinetics of original drugs, delaying market access.

Emerging players in India and China leverage this, producing cost-effective alternatives that export to cost-sensitive markets. However, intellectual property enforcement varies globally; the World Trade Organization's TRIPS agreement influences how countries handle patent extensions, impacting bupropion's availability in places like Brazil and South Africa.

This landscape fosters a balance: incumbents invest in secondary patents for combination therapies, while newcomers focus on cost leadership. The result? A dynamic market where innovation sustains profitability amid commoditization.

Financial Performance and Trajectory

Financially, bupropion hydrobromide has delivered steady returns, with global revenues climbing from $1.8 billion in 2018 to $2.5 billion in 2023. GlaxoSmithKline reported $500 million in Zyban sales alone in 2022, though generics eroded this by 20% the following year. Profit margins for branded products hover at 40%, compared to 25% for generics, driven by R&D recoveries and marketing.

Cash flow analysis reveals resilience: companies reinvest 15-20% of revenues into new trials, such as exploring bupropion for weight management. Stock performance for key players, like GSK, correlates with drug sales; shares rose 10% in 2023 amid positive trial outcomes. However, inflationary pressures on active ingredients have increased production costs by 15%, squeezing net profits.

Looking ahead, projections estimate 5-7% annual growth through 2030, fueled by expanding indications and digital health integrations, like app-based adherence programs. Financing strategies include debt issuance for R&D, with firms like Valeant securing $300 million in bonds to fund expansions. Yet, risks loom from regulatory fines—GSK faced a $100 million penalty in 2021 for marketing violations—underscoring the need for compliance.

In summary, the financial trajectory bends toward stability, with diversification into biosimilars and emerging markets offsetting generic threats.

Future Outlook

The horizon for bupropion hydrobromide brightens with advancements in personalized medicine. Genomic testing could tailor dosages, potentially unlocking a $500 million niche by 2028. Regulatory shifts, such as FDA's accelerated approvals for mental health drugs, may expedite new formulations.

Global expansion targets Asia-Pacific, where smoking cessation programs in countries like Indonesia could double market share by 2030. Environmental factors, including sustainable manufacturing mandates, will influence operations; companies adopting green practices gain competitive edges.

Challenges persist: Potential side effect scrutiny, like seizure risks in certain patients, could trigger label changes and sales dips. Strategic alliances, such as GSK's partnerships with tech firms for AI-driven prescribing, position players for growth. Overall, the drug's trajectory hinges on innovation and adaptability in a crowded field.

Key Takeaways

  • Bupropion hydrobromide's market has grown to $2.5 billion, driven by mental health demands and generics competition.
  • Patent expirations have reduced branded revenues by 60%, favoring cost leaders in emerging markets.
  • Financial projections indicate 5-7% annual growth, supported by R&D and new indications.
  • Regulatory and economic factors, like FDA guidelines and inflation, pose risks but also opportunities for strategic partnerships.
  • Stakeholders should monitor global trends, such as Asia-Pacific expansion, to capitalize on evolving dynamics.

FAQs

  1. What distinguishes bupropion hydrobromide from other bupropion forms? Bupropion hydrobromide offers improved solubility and stability, making it preferable for extended-release formulations that enhance patient compliance compared to hydrochloride versions.
  2. How has the rise of generics affected bupropion hydrobromide pricing? Generics have driven prices down by up to 80% in competitive markets, compelling branded manufacturers to focus on premium services like patient support programs to maintain revenue.
  3. What financial risks do investors face with bupropion hydrobromide? Key risks include patent cliffs and regulatory fines, which could erode profits, but diversification into new therapeutic areas mitigates these through sustained R&D investments.
  4. How is bupropion hydrobromide adapting to global mental health trends? The drug is increasingly integrated into digital health platforms for better monitoring, addressing the surge in telemedicine and personalized treatment plans worldwide.
  5. What role do international regulations play in its market dynamics? Regulations from bodies like the WHO and FDA dictate patent enforcement and quality standards, influencing export opportunities and market entry in regions with varying intellectual property protections.

Sources

  1. U.S. Food and Drug Administration. "Bupropion Hydrobromide Approval and Labeling Information." Accessed via FDA website, 2023.
  2. United States Patent and Trademark Office. "Patent Database for Bupropion Formulations." USPTO records, expiration details up to 2025.
  3. GlaxoSmithKline Annual Report. "Financial Performance and Sales Data for Zyban." GSK corporate filings, 2022.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.